Silence Therapeutics plc Cash and Cash Equivalents
Silence Therapeutics plc (SLN) had Cash and Cash Equivalents of $72.05 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-10
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $72.05M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $5.66M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $11.28M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $82.03M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $72.05M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $5.66M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $11.28M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $82.03M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $41.74M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $64.89M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $121.33M 10-K · filed 2026-03-05 |
| 2023-12-31 | $68.79M 10-K · filed 2025-02-27 |